Business
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury
CARLSBAD, Calif., August 04, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, announced today that the first-ever chronic spinal cord injury patient has been treated in the Company’s DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical study at UC San Die
About this update from Lineage Cell Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1740,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/868358d51bcef71cc61a357e51a2300c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aoQKFJU3H3_8QwGPV9RUNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/868358d51bcef71cc61a357e51a2300c","width":960,"height":199},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/JPU21MF9uR.fX9aKUO7efg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00OTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/868358d51bcef71cc61a357e51a2300c","width":1200,"height":248}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Successful First-In-Human Use of New Parenchymal Spinal Delivery System","length":71,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"First-ever Administration of OPC1 to a Chronic Injury Patient","length":61,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":132,"olType":false},{"type":"text","content":"CARLSBAD, Calif., August 04, 2025--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, announced today that the first-ever chronic spinal cord injury patient has been treated in the Company’s DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical study at UC San Diego Health. The DOSED study is designed to evaluate the safety and utility of a new parenchymal spinal delivery system, a novel delivery device developed to deliver OPC1 directly to the site of injury in patients with spinal cord injury (SCI), and will enroll both subacute (between 21 to 42 days following injury) and chronic (between 1 to 5 years following injury) SCI patients. OPC1 is an investigational, allogeneic stem cell-derived cell transplant, comprised of oligodendrocyte progenitor cells. OPC1 is designed to replace or support cells in the injured spinal cord that are absent or dysfunctional due to traumatic injury and is intended to help restore or augment functional activity in persons suffering from an ...